Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489358 · ClinicalTrials.gov registry record · Phase 1
Chikungunya Virus Vaccine Trial in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01489358 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants.
The verdict
NCT01489358, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Background: \- Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death. But the joint pain, which may be directly related to the infecting virus, may be severe and last for several months. CHIKV outbreaks are most common in Africa, India, and Asia. A new experimental vaccine for CHIKV has been developed, and researchers are testing it in healthy adults. Participants cannot develop CHIKV from this vaccine. Objectives: \- To test the safety and effectiveness of a Chikungunya virus vaccine. Eligibility: \- Healthy individuals between 18 and 50 years of age. Design: * This study, including vaccine doses and followup tests, will last about 44 weeks. Participants will have three vaccination visits, six followup clinic visits, and three telephone contacts during this study. Vaccination visits will take about 4 hours. Most other clinic visits will usually take 2 hours. The telephone contacts will take about 15 minutes. * Participants will be screened with a physical exam and medical history. Blood samples will also be collected. * Participants will be assigned to one of three dose groups. Information about doses will be provided before the start of the vaccinations. * Vaccine injections will be given at the start of the study, at 4 weeks, and at 20 weeks. Participants will be asked to keep an eye on the injection site for 7 days and to notify researchers if there are any side effects. * Participants will be monitored throughout the study with blood samples and clinic visits.
Interventions
- BIOLOGICAL VRC-CHKVLP059-00-VP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489358
The ClinicalTrials.gov registry entry for NCT01489358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VRC-CHKVLP059-00-VP is the first listed.
NCT01489358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489358 about?
NCT01489358 is a clinical study titled "Chikungunya Virus Vaccine Trial in Healthy Adults". Background: \- Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death. But the joint pain, which may be directly related to the infecting virus, may be severe and last for several months. C...
What is the current status of trial NCT01489358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2011-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01489358?
The interventions under investigation include: VRC-CHKVLP059-00-VP (BIOLOGICAL).
Who is sponsoring clinical trial NCT01489358?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.